Acumen amends bylaws to adopt universal proxy rules and DGCL updates

Acumen Pharmaceuticals, Inc.

Board adopted amended bylaws effective March 9, 2023, to comply with SEC Rule 14a-19 (universal proxy) and recent DGCL changes.
Enhanced disclosure requirements for stockholder director nominations, including background info and proxy solicitation intent.
Company will disregard nominations if stockholder fails to comply with Rule 14a-19 after providing notice.
Stockholders soliciting proxies must use a proxy card other than white; white card reserved for Board use.
Updated provisions on meeting adjournment procedures and stockholder list to reflect DGCL amendments.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Acumen Pharmaceuticals, Inc.: Adopted amended and restated bylaws including enhancements to stockholder nomination procedures and updates for universal proxy rules and DGCL changes (effective 2023-03-09).

Change: bylaw amendment
Effective: 2023-03-09

Exact text from the filing

On March 9, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Acumen Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.